SELLAS Life Sciences Group, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
SELLAS Life Sciences Group, Inc. (SLS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $307.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $154.00K, a 3.36% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $153.00K, a 4.08% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $154.00K, a 4.05% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $147.00K, a 7.30% increase year-over-year.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $597.00K, a 6.42% increase from fiscal 2024.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $561.00K, a 13.33% increase from fiscal 2023.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $495.00K, a 8.32% increase from fiscal 2022.
- SELLAS Life Sciences Group, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $457.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $307.00K 10-Q · filed 2026-08-11 | $461.00K derived: sum of 3 quarters · filed 2026-08-11 | $608.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $153.00K 10-Q · filed 2026-05-12 | $307.00K derived: sum of 2 quarters · filed 2026-05-12 | $454.00K derived: sum of 3 quarters · filed 2026-05-12 | $603.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $301.00K derived: sum of 2 quarters · filed 2026-03-19 | $450.00K derived: sum of 3 quarters · filed 2026-08-11 | $597.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $296.00K derived: sum of 2 quarters · filed 2026-08-11 | $443.00K 10-Q · filed 2025-11-12 | $591.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $149.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $296.00K 10-Q · filed 2026-08-11 | $444.00K derived: sum of 3 quarters · filed 2026-08-11 | $581.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $147.00K 10-Q · filed 2026-05-12 | $295.00K derived: sum of 2 quarters · filed 2026-05-12 | $432.00K derived: sum of 3 quarters · filed 2026-05-12 | $570.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $285.00K derived: sum of 2 quarters · filed 2026-03-19 | $423.00K derived: sum of 3 quarters · filed 2026-03-19 | $561.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $275.00K derived: sum of 2 quarters · filed 2025-11-12 | $413.00K 10-Q · filed 2025-11-12 | $541.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $276.00K 10-Q · filed 2025-08-12 | $404.00K derived: sum of 3 quarters · filed 2025-08-12 | $526.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $138.00K 10-Q · filed 2025-05-13 | $266.00K derived: sum of 2 quarters · filed 2025-05-13 | $388.00K derived: sum of 3 quarters · filed 2025-05-13 | $546.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $250.00K derived: sum of 2 quarters · filed 2025-03-20 | $408.00K derived: sum of 3 quarters · filed 2025-03-20 | $495.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $280.00K derived: sum of 2 quarters · filed 2024-11-13 | $367.00K 10-Q · filed 2024-11-13 | $490.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $245.00K 10-Q · filed 2024-08-13 | $368.00K derived: sum of 3 quarters · filed 2024-08-13 | $575.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $87.00K 10-Q · filed 2024-05-14 | $210.00K derived: sum of 2 quarters · filed 2024-05-14 | $417.00K derived: sum of 3 quarters · filed 2024-05-14 | $499.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $330.00K derived: sum of 2 quarters · filed 2024-03-28 | $412.00K derived: sum of 3 quarters · filed 2024-03-28 | $457.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $289.00K derived: sum of 2 quarters · filed 2023-11-09 | $334.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $127.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $45.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |